Up a level |
Palmieri, Carlo ORCID: 0000-0001-9496-2718, Stein, Rob C, Liu, Xinxue, Hudson, Emma, Nicholas, Hanna, Sasano, Hironobu, Guestini, Fouzia, Holcombe, Chris, Barrett, Sophie, Kenny, Laura et al (show 5 more authors)
(2017)
IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.
BREAST CANCER RESEARCH AND TREATMENT, 165 (2).
pp. 343-353.
Hill, Matilda, Iro, Mildred, Sadarangani, Manish, Absoud, Michael, Cantrell, Liberty, Chong, Kling, Clark, Christopher, Easton, Ava, Gray, Victoria, Kneen, Rachel et al (show 9 more authors)
(2023)
Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial.
BMJ open, 13 (11).
e072134-e072134.
Liu, Xinxue, Wright, Annie, Feng, Shuo, Janani, Leila, Aley, Parvinder K, Babbage, Gavin, Baker, Jonathan, Baxter, David, Bawa, Tanveer, Bula, Marcin et al (show 50 more authors)
(2023)
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
JOURNAL OF INFECTION, 87 (1).
pp. 18-26.
Liu, Xinxue, Munro, Alasdair PS, Feng, Shuo, Janani, Leila, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna et al (show 48 more authors)
(2022)
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.
JOURNAL OF INFECTION, 84 (6).
pp. 795-813.
Liu, Xinxue, Munro, Alasdair PS, Feng, Shuo, Janani, Leila, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna et al (show 48 more authors)
(2023)
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial (vol 84, pg 795, 2022).
JOURNAL OF INFECTION, 86 (5).
pp. 540-541.
Smith, Christopher ORCID: 0000-0001-7369-2034, Smith, Emma, Rydlova, Anna, Varro, Robert, Hinton, Jay CD ORCID: 0000-0003-2671-6026, Gordon, Melita A ORCID: 0000-0002-0629-0884, Choy, Robert KM, Liu, Xinxue ORCID: 0000-0003-1107-0365, Pollard, Andrew J ORCID: 0000-0001-7361-719X, Chiu, Christopher et al (show 2 more authors)
(2024)
Protocol for the challenge non-typhoidal <i>Salmonella</i> (CHANTS) study: a first-in-human, in-patient, double-blind, randomised, safety and dose-escalation controlled human infection model in the UK.
BMJ open, 14 (1).
e076477-.
Munro, Alasdair PS, Janani, Leila, Cornelius, Victoria, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna, Dodd, Kate et al (show 44 more authors)
(2021)
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
LANCET, 398 (10318).
pp. 2258-2276.
Munro, Alasdair PS, Feng, Shuo, Janani, Leila, Cornelius, Victoria, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna et al (show 45 more authors)
(2022)
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
LANCET INFECTIOUS DISEASES, 22 (8).
pp. 1131-1141.
Jin, Celina, Gibani, Malick M, Pennington, Shaun H, Liu, Xinxue, Ardrey, Alison, Aljayyoussi, Ghaith, Moore, Maria, Angus, Brian, Parry, Christopher M ORCID: 0000-0001-7563-7282, Biagini, Giancarlo A et al (show 2 more authors)
(2019)
Treatment responses to Azithromycin and Ciprofloxacin in uncomplicated <i>Salmonella</i> Typhi infection: A comparison of Clinical and Microbiological Data from a Controlled Human Infection Model.
PLOS NEGLECTED TROPICAL DISEASES, 13 (12).
e0007955-.